 | Up a level |
Journal Article
Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'Sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S87 - 2. HOBOKEN: WILEY. ISSN 1545-5017
Ackermann, S., Cartolano, M., Hero, B., Roderwieser, A., Bartenhagen, C., Rosswog, C., Hertwig, F., Simon, T., Eggert, A., Speleman, F., Buettner, R., O'sullivan, R., Thomas, R., Berthold, F., Vandesompele, J., Schramm, A., Westermann, F., Schulte, J., Peifer, M. and Fischer, M. (2018). A Mechanistic Classification of Clinical Phenotypes in Neuroblastoma. Pediatr. Blood Cancer, 65. S. S234 - 1. HOBOKEN: WILEY. ISSN 1545-5017
Berthold, F., Faldum, A., Ernst, A., Boos, J., Dilloo, D., Eggert, A., Fischer, M., Fruehwald, M., Henze, G., Klingebiel, T., Kratz, C., Kremens, B., Krug, B., Leuschner, I, Schmidt, M., Schmidt, R., Schumacher-Kuckelkorn, R., von Schweinitz, D., Schilling, F. H., Theissen, J., Volland, R., Hero, B. and Simon, T. (2020). Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann. Oncol., 31 (3). S. 422 - 430. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Deubzer, H., Fabian, J., Opitz, D., Althoff, K., Lodrini, M., Astrahantseff, K., Hero, B., Volland, R., Beckers, A., De Preter, K., Patil, N., Abba, M., Wuenchel, J., Thole, T., Hu, J., Schweitzer, L., Mechtersheimer, G., Carter, D., Cheung, B., Popanda, O., von Deimling, A., Henrich, K. O., Westermann, F., Schwab, M., Koster, J., Versteeg, R., Marshall, G., Speleman, F., Zoeller, M., Allgayer, H., Fischer, M., Berthold, F., Kulozik, A., Witt, O., Schulte, J. and Eggert, A. (2015). MYCN TRANSCRIPTIONALLY REPRESSES CD9 TO TRIGGER AN INVASION-METASTASIS CASCADE IN NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S150 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017
Eggert, A., Schramm, A., Koester, J., Assenov, Y., Kristina, A., Engesser, A., Kahlert, Y., Theissen, J., Hero, B., Roels, F., Peifer, M., Astrahantseff, K., Depreter, K., Lode, H., Speleman, F., Schmezer, P., Westermann, F., Rahmann, S., Fischer, M. and Schulte, J. (2015). INTEGRATED GENOMIC ANALYSIS IDENTIFIES SPECIFIC ALTERATIONS AND ACTIVATION OF YAP IN RELAPSED NEUROBLASTOMA. Pediatr. Blood Cancer, 62. S. S145 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017
Hero, B., Simon, T., Lode, H., Eggert, A. and Berthold, F. (2017). Feasibility and Toxicity of Busulfan and Melphalan Conditioning Regimen in the Context of the German Induction Chemotherapy. Pediatr. Blood Cancer, 64. S. S34 - 2. HOBOKEN: WILEY. ISSN 1545-5017
Hero, B., Simon, T., Volland, R., Eggert, A., Fischer, M. and Berthold, F. (2015). BENIGN COURSE OF DISEASE IN LOCALIZED NEUROBLASTOMA SHOWING RELAPSE OR PROGRESSION. Pediatr. Blood Cancer, 62. S. S178 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1545-5017
Schmidt, M. C., Hero, B., Decarolis, B., Eggert, A., Berthold, F., Drzezga, A. and Simon, T. (2017). I-131-mIBG therapy in high-risk neuroblastoma patients at end of induction chemotherapy. Eur. J. Nucl. Med. Mol. Imaging, 44. S. S772 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Schmidt, M. C., Hero, B., Decarolis, B., Eggert, A., Berthold, F., Drzezga, A. and Simon, T. (2016). I-131-meta-iodobenzylguanidine therapy improves survival in high-risk neuroblastoma patients with I-123-mIBG positive residual metastatic disease. Eur. J. Nucl. Med. Mol. Imaging, 43. S. S31 - 1. NEW YORK: SPRINGER. ISSN 1619-7089
Schulte, J., Schramm, A., Koester, J., Westermann, F., Peifer, M., Fischer, M., Rahmann, S. and Eggert, A. (2016). Mutational dynamics between primary and relapse neuroblastoma involve genes relevant for mesenchymal transition. Oncol. Res. Treat., 39. S. 30 - 32. BASEL: KARGER. ISSN 2296-5262
Schulte, J. H., Schulte, S., Heukamp, L. C., Astrahantseff, K., Stephan, H., Fischer, M., Schramm, A. and Eggert, A. (2013). Targeted Therapy for Neuroblastoma: ALK Inhibitors. Klinische Padiatr., 225 (6). S. 303 - 309. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-3824
Simon, T., Schmidt, M., Decarolis, B., Eggert, A., Berthold, F. and Hero, B. (2017). I-131-Meta-Iodobenzylguanidine (MIBG) Therapy Improves Survival in High-Risk Neuroblastoma Patients with MIBG Positive Residual Metastatic Disease. Pediatr. Blood Cancer, 64. S. S33 - 2. HOBOKEN: WILEY. ISSN 1545-5017